Abstract: An ultrasound probe (104) includes a probe head (134). The probe head includes a transducer array (136) with a transducing surface (137), an instrument guide (142), and a light source (140). A method includes emitting a light beam, from a light source disposed on and adjacent to a transducer array of an ultrasound imaging probe, in a direction opposite of a transducing surface of the transducer array, at an inside wall of a cavity of a subject or object. A laparoscopic ultrasound imaging probe includes a shaft, a body, an articulating member that couples the probe head, and a handle coupled to the elongate shaft. The articulating probe head includes a transducer array that generates an ultrasound signal that traverses an image plane of the transducer array, an instrument guide, and a light source arranged to emit light in a direction opposite of the image plane.

Abstract: An ultrasound imaging system (100) includes a transducer array (102). The transducer array includes a first set of transducer elements (206 or 208, 302 or 304) and a second set of transducer elements (208 or 206, 304 or 302). The first and second sets of transducer elements includes long axes and are angularly offset from each other by a non-zero angle with respect to the long axes. The ultrasound imaging system further includes a velocity processor (120) that processes echoes received by the first and second sets of transducer elements and determines an axial and two transverse flow velocity components based on the received echoes.

Abstract: An elongate probe (204) including a probe head (214) with a transducer array (216), a shaft (210) and an articulating member (212). The articulating member is located between the probe head and the shaft. The articulating member is configured to articulate between a position in which the probe head extends along a longitudinal axis of the probe and at least one articulated position in which the probe head extends at a non-zero angle from the longitudinal axis of the probe. The probe further includes a stiffener (224) configured to controllably move from a retracted position to an extended position at which the stiffener inhibits articulation of the articulating member.

Abstract: An ultrasound probe (104) includes a probe head (134). The probe head includes a transducer array (136) with a transducing surface (137), an instrument guide (142), and a light source (140). A method includes emitting a light beam, from a light source disposed on and adjacent to a transducer array of an ultrasound imaging probe, in a direction opposite of a transducing surface of the transducer array, at an inside wall of a cavity of a subject or object. A laparoscopic ultrasound imaging probe includes a shaft, a body, an articulating member that couples the probe head, and a handle coupled to the elongate shaft. The articulating probe head includes a transducer array that generates an ultrasound signal that traverses an image plane of the transducer array, an instrument guide, and a light source arranged to emit light in a direction opposite of the image plane.

Abstract: An ultrasound imaging system (100) includes a transducer array (102). The transducer array includes a first set of transducer elements (206 or 208, 302 or 304) and a second set of transducer elements (208 or 206, 304 or 302). The first and second sets of transducer elements includes long axes and are angularly offset from each other by a non-zero angle with respect to the long axes. The ultrasound imaging system further includes a velocity processor (120) that processes echoes received by the first and second sets of transducer elements and determines an axial and two transverse flow velocity components based on the received echoes.

Abstract: An elongate probe (204) including a probe head (214) with a transducer array (216), a shaft (210) and an articulating member (212). The articulating member is located between the probe head and the shaft. The articulating member is configured to articulate between a position in which the probe head extends along a longitudinal axis of the probe and at least one articulated position in which the probe head extends at a non-zero angle from the longitudinal axis of the probe. The probe further includes a stiffener (224) configured to controllably move from a retracted position to an extended position at which the stiffener inhibits articulation of the articulating member.

Abstract: Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

Abstract: Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

Abstract: Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

Abstract: Oligonucleotides directed against the Apo-B100 gene are provided for modulating the expression of Apo-B100. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the Apo-B100. Methods of using these compounds for modulation of Apo-B100 expression and for the treatment of diseases associated with either overexpression of Apo-B100, expression of mutated Apo-B100 or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

Abstract: The present invention relates to the field of sterilization of items that are sensitive to e.g. temperature, pH, positive or negative pressure, radiation or oxidation. More particularly, the invention concerns a method, the use of this method and an apparatus for sterilization or disinfection, comprising the steps of contacting one or more item or part of an item with (a) a water-based fluid containing at least one enzyme, and (b) a substantially water-free environment with a gas having oxidative properties, where said step (a) precedes said step (b). According to the invention, items can be sterilized that are otherwise impaired by conventional sterilization procedures, such as laboratory items, medical items, dental items, military items, biological items, and food processing-related items.

Abstract: Oligonucleotides directed against the Ha-ras gene are provided for modulating the expression of Ha-ras. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the Ha-ras. Methods of using these compounds for modulation of Ha-ras expression and for the treatment of diseases associated with either overexpression of Ha-ras, expression of mutated Ha-ras or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

Abstract: Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

Abstract: Oligonucleotides directed against the Ha-ras gene are provided for modulating the expression of Ha-ras. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the Ha-ras. Methods of using these compounds for modulation of Ha-ras expression and for the treatment of diseases associated with either overexpression of Ha-ras, expression of mutated Ha-ras or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

Abstract: Oligonucleotides directed against the TRX gene are provided for modulating the expression of TRX. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the TRX. Methods of using these compounds for modulation of TRX expression and for the treatment of diseases associated with either overexpression of TRX, expression of mutated TRX or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.

Abstract: The invention relates to therapeutic applications of LNA-modified oligonucleotides. In particular, the invention provides methods for treatment of infectious diseases and disorders caused by viruses, bacteria, protozoa or fungi. Preferably, administration of an LNA-modified oligonucleotide modulates expression of a targeted gene associated with the replication or infectivity of a virus, virulence genes, host immune modulating genes and the like. That is, preferred use of LNA-modified oligonucleotide provides an antisense-type therapy with selective modulation of gene expression of predetermined targets.